A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML

Leuk Lymphoma. 2022 Dec;63(13):3257-3260. doi: 10.1080/10428194.2022.2118532. Epub 2022 Sep 8.

Authors

Affiliations

¹ UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
² Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
³ Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
⁴ Biostatistics Facility, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Cytogenetic Analysis
Cytogenetics
Humans
Induction Chemotherapy*
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Mutation
Nomograms
Nuclear Proteins / genetics
Prognosis
Tumor Suppressor Protein p53 / genetics
fms-Like Tyrosine Kinase 3

Substances

Nuclear Proteins
fms-Like Tyrosine Kinase 3
TP53 protein, human
Tumor Suppressor Protein p53

Grants and funding